{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:46:18Z","timestamp":1789454778283,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-50819-7","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T13:03:07Z","timestamp":1723122187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Nano-anticoagulant based on carrier-free low molecular weight heparin and octadecylamine with an albumin shuttling effect"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3405-198X","authenticated-orcid":false,"given":"Jae-Hyeon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8489-0276","authenticated-orcid":false,"given":"Hansol","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3099-8412","authenticated-orcid":false,"given":"Gaeun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0851-7843","authenticated-orcid":false,"given":"Seho","family":"Kweon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Jin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8197-7317","authenticated-orcid":false,"given":"Minho","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1409-9883","authenticated-orcid":false,"given":"Jun-Hyuck","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2295-3507","authenticated-orcid":false,"given":"Seong-Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1418-1768","authenticated-orcid":false,"given":"Han-Gil","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6332-3278","authenticated-orcid":false,"given":"Jooho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"50819_CR1","doi-asserted-by":"publisher","first-page":"119818","DOI":"10.1016\/j.carbpol.2022.119818","volume":"295","author":"P Wang","year":"2022","unstructured":"Wang, P. et al. Heparin: an old drug for new clinical applications. Carbohydr. Polym. 295, 119818 (2022).","journal-title":"Carbohydr. Polym."},{"key":"50819_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.pmbts.2019.02.002","volume":"163","author":"C Hao","year":"2019","unstructured":"Hao, C., Xu, H., Yu, L. & Zhang, L. Heparin: an essential drug for modern medicine. Prog. Mol. Biol. Transl. Sci. 163, 1\u201319 (2019).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"50819_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/pharmrev.122.000684","volume":"75","author":"J Hogwood","year":"2023","unstructured":"Hogwood, J., Mulloy, B., Lever, R., Gray, E. & Page, C. P. Pharmacology of heparin and related drugs: an update. Pharmacol. Rev. 75, 328\u2013379 (2023).","journal-title":"Pharmacol. Rev."},{"key":"50819_CR4","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/S0140-6736(22)02128-6","volume":"400","author":"IM Bistervels","year":"2022","unstructured":"Bistervels, I. M. et al. Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial. Lancet 400, 1777\u20131787 (2022).","journal-title":"Lancet"},{"key":"50819_CR5","doi-asserted-by":"publisher","first-page":"141S","DOI":"10.1378\/chest.08-0689","volume":"133","author":"J Hirsh","year":"2008","unstructured":"Hirsh, J. et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 141S\u2013159S (2008).","journal-title":"Chest"},{"key":"50819_CR6","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1160\/TH08-01-0032","volume":"99","author":"E Gray","year":"2008","unstructured":"Gray, E., Mulloy, B. & Barrowcliffe, T. W. Heparin and low-molecular-weight heparin. J. Thromb. Haemost. 99, 807\u2013818 (2008).","journal-title":"J. Thromb. Haemost."},{"key":"50819_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/bs.pmbts.2019.02.003","volume":"163","author":"C Hao","year":"2019","unstructured":"Hao, C., Sun, M. J., Wang, H. M., Zhang, L. J. & Wang, W. Low molecular weight heparins and their clinical applications. Prog. Mol. Biol. Transl. Sci. 163, 21\u201339 (2019).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"50819_CR8","unstructured":"The Insight Partners, Low molecular weight heparin market size and growth analysis. The Insight Partners, TIPRE00026174, (2021)."},{"key":"50819_CR9","first-page":"I19","volume":"110","author":"JI Weitz","year":"2004","unstructured":"Weitz, J. I. New anticoagulants for treatment of venous thromboembolism. Arterioscler. Thromb. Vasc. Biol. 110, I19\u2013I26 (2004).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"50819_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-200241002-00001","volume":"41","author":"F Donat","year":"2002","unstructured":"Donat, F. et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin. Pharmacokinet. 41, 1\u20139 (2002).","journal-title":"Clin. Pharmacokinet."},{"key":"50819_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1055\/s-2007-1004351","volume":"11","author":"E Coyne","year":"1985","unstructured":"Coyne, E. From heparin to heparin fractions and derivatives. Semin. Thromb. Hemost. 11, 10\u201312 (1985).","journal-title":"Semin. Thromb. Hemost."},{"key":"50819_CR12","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/0006-291X(83)90550-8","volume":"116","author":"J Choay","year":"1983","unstructured":"Choay, J. et al. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem. Biophys. Res. Commun. 116, 492\u2013499 (1983).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"50819_CR13","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/j.drudis.2020.09.011","volume":"25","author":"SN Baytas","year":"2020","unstructured":"Baytas, S. N. & Linhardt, R. J. Advances in the preparation and synthesis of heparin and related products. Drug Discov. Today 25, 2095\u20132109 (2020).","journal-title":"Drug Discov. Today"},{"key":"50819_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF00421226","volume":"48","author":"I Bjork","year":"1982","unstructured":"Bjork, I. & Lindahl, U. Mechanism of the anticoagulant action of heparin. Mol. Cell. Biochem. 48, 161\u2013182 (1982).","journal-title":"Mol. Cell. Biochem."},{"key":"50819_CR15","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/S0167-5273(16)12004-2","volume":"212","author":"G Cassinelli","year":"2016","unstructured":"Cassinelli, G. & Naggi, A. Old and new applications of non-anticoagulant heparin. Int. J. Cardiol. 212, S14\u2013S21 (2016).","journal-title":"Int. J. Cardiol."},{"key":"50819_CR16","doi-asserted-by":"publisher","first-page":"120930","DOI":"10.1016\/j.carbpol.2023.120930","volume":"314","author":"JH Lee","year":"2023","unstructured":"Lee, J. H. et al. Doxorubicin covalently conjugated heparin displays anti-cancer activity as a self-assembled nanoparticle with a low-anticoagulant effect. Carbohydr. Polym. 314, 120930 (2023).","journal-title":"Carbohydr. Polym."},{"key":"50819_CR17","first-page":"7030","volume":"9","author":"A Plucinski","year":"2021","unstructured":"Plucinski, A., Lyu, Z. & Schmidt, B. V. K. J. Polysaccharide nanoparticles: from fabrication to applications. J. Mater. Chem. 9, 7030\u20137062 (2021).","journal-title":"J. Mater. Chem."},{"key":"50819_CR18","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jconrel.2021.01.033","volume":"331","author":"C Lei","year":"2021","unstructured":"Lei, C. et al. Hyaluronic acid and albumin based nanoparticles for drug delivery. J. Controll. Release 331, 416\u2013433 (2021).","journal-title":"J. Controll. Release"},{"key":"50819_CR19","doi-asserted-by":"publisher","first-page":"119793","DOI":"10.1016\/j.carbpol.2022.119793","volume":"294","author":"X Yang","year":"2022","unstructured":"Yang, X. et al. Strategies for sustained release of heparin: a review. Carbohydr. Polym. 294, 119793 (2022).","journal-title":"Carbohydr. Polym."},{"key":"50819_CR20","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1166\/jnn.2015.9816","volume":"15","author":"C Pazzini","year":"2015","unstructured":"Pazzini, C. et al. Polymeric nanoparticles of enoxaparin as a delivery system: in vivo evaluation in normal rats and in a venous thrombosis rat model. J. Nanosci. Nanotechnol. 15, 4837\u20134843 (2015).","journal-title":"J. Nanosci. Nanotechnol."},{"key":"50819_CR21","first-page":"3358","volume":"6","author":"Y Zeng","year":"2021","unstructured":"Zeng, Y. et al. Polysaccharide-based nanomedicines for cancer immunotherapy: a review. Bioact. Mater. 6, 3358\u20133382 (2021).","journal-title":"Bioact. Mater."},{"key":"50819_CR22","doi-asserted-by":"publisher","first-page":"101471","DOI":"10.1016\/j.jddst.2019.101471","volume":"55","author":"E Karami","year":"2020","unstructured":"Karami, E., Behdani, M. & Kazemi-Lomedasht, F. Albumin nanoparticles as nanocarriers for drug delivery: Focusing on antibody and nanobody delivery and albumin-based drugs. J. Drug Deliv. Sci. Technol. 55, 101471 (2020).","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"50819_CR23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1126\/scitranslmed.abb0580","volume":"12","author":"M Bern","year":"2020","unstructured":"Bern, M. et al. An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics. Sci. Transl. Med. 12, 565 (2020).","journal-title":"Sci. Transl. Med."},{"key":"50819_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41551-020-00627-3","volume":"5","author":"A Ishihara","year":"2021","unstructured":"Ishihara, A. et al. Prolonged residence of an albumin-IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis. Nat. Biomed. Eng. 5, 387\u2013398 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"50819_CR25","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1021\/acs.jmedchem.2c01021","volume":"66","author":"F Zaragoza","year":"2023","unstructured":"Zaragoza, F. Non-covalent albumin ligands in FDA-approved therapeutic peptides and proteins. J. Med. Chem. 66, 3656\u20133663 (2023).","journal-title":"J. Med. Chem."},{"key":"50819_CR26","doi-asserted-by":"publisher","first-page":"11369","DOI":"10.1021\/acsnano.1c00799","volume":"15","author":"G Kwak","year":"2021","unstructured":"Kwak, G. et al. A Trojan-Horse strategy by in situ piggybacking onto endogenous albumin for tumor-specific neutralization of oncogenic MicroRNA. ACS Nano 15, 11369\u201311384 (2021).","journal-title":"ACS Nano"},{"key":"50819_CR27","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jconrel.2022.11.034","volume":"353","author":"P Famta","year":"2023","unstructured":"Famta, P. et al. Albumin-hitchhiking: fostering the pharmacokinetics and anticancer therapeutics. J. Controll. Release 353, 166\u2013185 (2023).","journal-title":"J. Controll. Release"},{"key":"50819_CR28","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1021\/acs.molpharmaceut.1c00046","volume":"18","author":"A Spada","year":"2021","unstructured":"Spada, A., Emami, J., Tuszynski, J. A. & Lavasanifar, A. The uniqueness of albumin as a carrier in nanodrug delivery. Mol. Pharm. 18, 1862\u20131894 (2021).","journal-title":"Mol. Pharm."},{"key":"50819_CR29","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1021\/acs.bioconjchem.9b00760","volume":"30","author":"W Um","year":"2019","unstructured":"Um, W. et al. A comparative study on albumin-binding molecules for targeted tumor delivery through covalent and noncovalent approach. Bioconjugate Chem. 30, 3107\u20133118 (2019).","journal-title":"Bioconjugate Chem."},{"key":"50819_CR30","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jconrel.2011.07.031","volume":"157","author":"AO Elzoghby","year":"2012","unstructured":"Elzoghby, A. O., Samy, W. M. & Elgindy, N. A. Albumin-based nanoparticles as potential controlled release drug delivery systems. J. Controll. Release 157, 168\u2013182 (2012).","journal-title":"J. Controll. Release"},{"key":"50819_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jconrel.2022.05.038","volume":"348","author":"S Linciano","year":"2022","unstructured":"Linciano, S., Moro, G., Zorzi, A. & Angelini, A. Molecular analysis and therapeutic applications of human serum albumin-fatty acid interactions. J. Controll. Releas. 348, 115\u2013126 (2022).","journal-title":"J. Controll. Releas."},{"key":"50819_CR32","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1006\/jmbi.2000.4158","volume":"303","author":"AA Bhattacharya","year":"2000","unstructured":"Bhattacharya, A. A., Grune, T. & Curry, S. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J. Mol. Biol. 303, 721\u2013732 (2000).","journal-title":"J. Mol. Biol."},{"key":"50819_CR33","doi-asserted-by":"crossref","unstructured":"Guerrini, M. & Bisio, A. Low-molecular-weight heparins: differential characterization\/physical characterization. Handb. Exp. Pharmacol. 207, 127\u2013157 (2012).","DOI":"10.1007\/978-3-642-23056-1_7"},{"key":"50819_CR34","doi-asserted-by":"publisher","first-page":"10520","DOI":"10.1021\/acs.jmedchem.6b00936","volume":"59","author":"J Park","year":"2016","unstructured":"Park, J. et al. End-site-specific conjugation of enoxaparin and tetradeoxycholic acid using nonenzymatic glycosylation for oral delivery. J. Med. Chem. 59, 10520\u201310529 (2016).","journal-title":"J. Med. Chem."},{"key":"50819_CR35","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41578-021-00379-9","volume":"6","author":"C Horejs","year":"2021","unstructured":"Horejs, C. From lipids to lipid nanoparticles to mRNA vaccines. Nat. Rev. Mater. 6, 1075\u20131076 (2021).","journal-title":"Nat. Rev. Mater."},{"key":"50819_CR36","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.jconrel.2020.10.014","volume":"329","author":"S Karaosmanoglu","year":"2021","unstructured":"Karaosmanoglu, S. et al. Carrier-free nanodrugs for safe and effective cancer treatment. J. Controll. Release 329, 805\u2013832 (2021).","journal-title":"J. Controll. Release"},{"key":"50819_CR37","doi-asserted-by":"publisher","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","volume":"119","author":"J Hirsh","year":"2001","unstructured":"Hirsh, J. et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119, 64S\u201394S (2001).","journal-title":"Chest"},{"key":"50819_CR38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-2007-996417","volume":"25","author":"RJ Linhardt","year":"1999","unstructured":"Linhardt, R. J. & Gunay, N. S. Production and chemical processing of low molecular weight heparins. Semin. Thromb. Hemost. 25, 5\u201316 (1999).","journal-title":"Semin. Thromb. Hemost."},{"key":"50819_CR39","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3109\/10409239509083490","volume":"30","author":"S Ernst","year":"1995","unstructured":"Ernst, S., Langer, R., Cooney, C. L. & Sasisekharan, R. Enzymatic degradation of glycosaminoglycans. Crit. Rev. Biochem. Mol. Biol. 30, 387\u2013444 (1995).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"50819_CR40","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau, J. et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J. Med. Chem. 58, 7370\u20137380 (2015).","journal-title":"J. Med. Chem."},{"key":"50819_CR41","doi-asserted-by":"publisher","first-page":"21891","DOI":"10.1021\/acsomega.9b02883","volume":"4","author":"Q Liu","year":"2019","unstructured":"Liu, Q. et al. Serum albumin-peptide conjugates for simultaneous heparin binding and detection. ACS Omega 4, 21891\u201321899 (2019).","journal-title":"ACS Omega"},{"key":"50819_CR42","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/ph10030066","volume":"10","author":"KM Arnold","year":"2017","unstructured":"Arnold, K. M. et al. Modernization of enoxaparin molecular weight determination using homogeneous standards. Pharmaceuticals 10, 66 (2017).","journal-title":"Pharmaceuticals"},{"key":"50819_CR43","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nbt.2528","volume":"31","author":"S Lee","year":"2013","unstructured":"Lee, S. et al. Scientific considerations in the review and approval of generic enoxaparin in the United States. Nat. Biotechnol. 31, 220\u2013226 (2013).","journal-title":"Nat. Biotechnol."},{"key":"50819_CR44","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/S0021-9258(19)61050-1","volume":"277","author":"SR Benedict","year":"2002","unstructured":"Benedict, S. R. A reagent for the detection of reducing sugars. J. Biol. Chem. 277, e5 (2002).","journal-title":"J. Biol. Chem."},{"key":"50819_CR45","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/17425255.2016.1194395","volume":"12","author":"E Sokolowska","year":"2016","unstructured":"Sokolowska, E., Kalaska, B., Miklosz, J. & Mogielnicki, A. The toxicology of heparin reversal with protamine: past, present and future. Expert Opin. Drug Metab. Toxicol. 12, 897\u2013909 (2016).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"50819_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37629-z","volume":"14","author":"M Peydayesh","year":"2023","unstructured":"Peydayesh, M. et al. Amyloid-polysaccharide interfacial coacervates as therapeutic materials. Nat. Commun. 14, 1848 (2023).","journal-title":"Nat. Commun."},{"key":"50819_CR47","doi-asserted-by":"publisher","first-page":"119013","DOI":"10.1016\/j.carbpol.2021.119013","volume":"279","author":"QY Meng","year":"2022","unstructured":"Meng, Q. Y. et al. Review on design strategies and considerations of polysaccharide-based smart drug delivery systems for cancer therapy. Carbohydr. Polym. 279, 119013 (2022).","journal-title":"Carbohydr. Polym."},{"key":"50819_CR48","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41563-022-01235-z","volume":"21","author":"KJM Bishop","year":"2022","unstructured":"Bishop, K. J. M. Self-assembly across scales. Nat. Mater. 21, 501\u2013502 (2022).","journal-title":"Nat. Mater."},{"key":"50819_CR49","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41570-022-00373-x","volume":"6","author":"S Chagri","year":"2022","unstructured":"Chagri, S., Ng, D. Y. W. & Weil, T. Designing bioresponsive nanomaterials for intracellular self-assembly. Nat. Rev. Chem. 6, 320\u2013338 (2022).","journal-title":"Nat. Rev. Chem."},{"key":"50819_CR50","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jconrel.2022.07.014","volume":"349","author":"T Waghule","year":"2022","unstructured":"Waghule, T., Saha, R. N., Alexander, A. & Singhvi, G. Tailoring the multi-functional properties of phospholipids for simple to complex self-assemblies. J. Controll. Release 349, 460\u2013474 (2022).","journal-title":"J. Controll. Release"},{"key":"50819_CR51","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coph.2019.03.009","volume":"46","author":"B Mulloy","year":"2019","unstructured":"Mulloy, B. The non-anticoagulant promise of heparin and its mimetics. Curr. Opin. Pharmacol. 46, 50\u201354 (2019).","journal-title":"Curr. Opin. Pharmacol."},{"key":"50819_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32281-5","volume":"13","author":"H Ni","year":"2022","unstructured":"Ni, H. et al. Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo. Nat. Commun. 13, 4766 (2022).","journal-title":"Nat. Commun."},{"key":"50819_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-21568-8","volume":"12","author":"FA Younis","year":"2022","unstructured":"Younis, F. A. et al. Preparation, physicochemical characterization, and bioactivity evaluation of berberine-entrapped albumin nanoparticles. Sci. Rep. 12, 17431 (2022).","journal-title":"Sci. Rep."},{"key":"50819_CR54","doi-asserted-by":"publisher","first-page":"2000536","DOI":"10.1002\/adhm.202000536","volume":"9","author":"SF Zhang","year":"2020","unstructured":"Zhang, S. F. et al. Heparin-coated albumin nanoparticles for drug combination in targeting inflamed intestine. Adv. Healthc. Mater. 9, 2000536 (2020).","journal-title":"Adv. Healthc. Mater."},{"key":"50819_CR55","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1042\/bj3240473","volume":"324","author":"RE Vilar","year":"1997","unstructured":"Vilar, R. E. et al. Nitric oxide degradation of heparin and heparan sulphate. Biochem. J. 324, 473\u2013479 (1997).","journal-title":"Biochem. J."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50819-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50819-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50819-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T14:13:28Z","timestamp":1723126408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50819-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["50819"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-50819-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3315746\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"assertion":[{"value":"1 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6769"}}